Prestige Biopharma Group is a fast-growing biopharmaceutical, specializing in the development and manufacturing of novel antibody, biosimilar, and vaccine.
🔬 Prestige Biopharma IDC is proud to be presenting at AAPS PharmSci 360 2026 in New Orleans, USA!
Our team will be presenting a poster on our chitosan hydrogel-based long-acting subcutaneous (SC) delivery system, developed using TUZNUE® (trastuzumab biosimilar). This study demonstrates improved drug retention and sustained release at the injection site, as well as enhanced anti-tumor efficacy in preclinical models of HER2-positive gastric and ovarian cancers — compared to a commercially available trastuzumab SC product.
As the pharmaceutical industry increasingly moves toward SC formulations to improve patient convenience, we believe our platform technology holds strong potential for broader application across antibody therapeutics and for partnerships with global pharmaceutical companies.
📌 Poster No.: T1130-02-10
📅 Date: 27th October 2026, 11:30 AM – 12:30 PM
🗺 Location: New Orleans, USA
We look forward to connecting with fellow researchers and industry partners at the event. If you are attending AAPS PharmSci 360 2026, we would love to meet you! 🤝
#PrestigeBiopharma #AAPS #AAPSPharmSci360 #Biosimilars #DrugDelivery #SubcutaneousDelivery #Trastuzumab #ChitosanHydrogel #Pharmaceuticals #InnovationForLife
We are excited to share that Prestige Biopharma will be attending the ESMO Congress 2026, taking place from 23–27 October 2026 at IFEMA Madrid, Spain.
At this year’s congress, we will be introducing our novel biologics and biosimilar pipeline, pancreatic cancer diagnostic kit, and subcutaneous delivery platform. We will place particular focus on two investigational molecules: PBP1510 (ulenistamab), a first-in-class monoclonal antibody targeting PAUF in pancreatic cancer, and PBP1710, a first-in-class antibody targeting CTHRC1 in solid tumors and fibrosis. Through discussions at our booth, we aim to gather expert perspectives, build scientific relationships, and explore opportunities for clinical development and collaboration.
Visit us at Booth #1022 to connect with one of our delegates, or reach out to schedule a meeting in advance. Guided by our vision of Innovation for Life, we look forward to seeing you in Madrid!
#PrestigeBiopharma #Biosimilars #PancreaticCancer #Antibody #ESMO26 #Pharmaceuticals #InnovationForLife
🎉 We are thrilled to share that Prestige Biopharma will be attending CPHI Milan 2026, the world's leading pharma partnering event.
At this event, our delegates will be available to discuss a broad range of partnership opportunities across our portfolio — from the continued commercialization of TUZNUE® (trastuzumab biosimilar) in Europe and beyond, to co-funding and co-development opportunities across our expanding biosimilars pipeline.
We will also be showcasing our innovative antibody therapeutics, PBP1510 and PBP1710, targeting cancers with high unmet need, as well as the breadth of our capabilities beyond biosimilars — spanning subcutaneous drug delivery and TASA™, our precision diagnostics platform. 🧪
Whether you are looking to explore licensing, co-funding, co-development, or commercialization opportunities in biosimilars — or reconnect to identify new areas of collaboration — we look forward to connecting with you.
Visit our booth to meet one of our delegates! 🤝
🗺 Location: Milan, Italy
📅 Dates: 6th - 8th October
📍 Booth No.: Hall 5, hashtag#5D114 (Integrated Pharma Zone)
#PrestigeBiopharma #CPHI #CPHIMilan2026 #Biologics #Biosimilars #Pharmaceuticals #InnovationForLife #GlobalPartnership
What if a single therapeutic approach could address fibrosis across multiple organs? At Prestige Biopharma, we are investigating exactly that with PBP1710, our anti-CTHRC1 monoclonal antibody under development as a potential treatment for fibrotic diseases.
Fibrosis — the excessive accumulation of scar tissue — is a shared pathological mechanism underlying serious diseases affecting the kidney, liver, and lungs. CTHRC1 is a protein that plays a key biological role in driving the fibrotic response, making it a compelling therapeutic target. PBP1710 is designed to modulate the key pathways associated with excessive fibrotic responses by selectively targeting CTHRC1, with the aim of interrupting the mechanisms that drive disease progression.
What makes PBP1710 particularly compelling is its potential as a broader therapeutic strategy. Because CTHRC1 may represent a shared mechanism across different organs and fibrotic conditions, PBP1710 could offer a platform approach — one antibody with the potential to address multiple diseases driven by the same underlying biology.
🎬 https://t.co/oEydNoCnwe
Watch our full latest video to learn more about the science behind PBP1710 and its potential to redefine how we approach fibrotic disease.
#Prestige #Prestigebiopharma #PBP1710 #Fibrosis #CTHRC1 #FibroticDiseases #TargetedTherapy #MonoclonalAntibody
At Prestige Biopharma, our commitment to overcoming some of medicine's most challenging therapeutic barriers continues with PBP1710, our first-in-class anti-CTHRC1 monoclonal antibody.
Pathological fibrosis remains a major obstacle across oncology and chronic fibrotic diseases. In solid tumors, dense fibrotic tissue can limit drug penetration and treatment effectiveness, while progressive tissue scarring drives diseases such as MASH and idiopathic pulmonary fibrosis (IPF).
PBP1710 is designed to target CTHRC1, a key regulator of pathological fibrosis implicated in both solid tumors and chronic fibrotic diseases. In preclinical studies, PBP1710 inhibited cancer cell migration and invasion and demonstrated significant synergy with paclitaxel and gemcitabine, supporting its potential across fibrotic solid tumors.
Supported by the Korea Drug Development Fund (KDDF) for solid tumor research and backed by a strong global patent portfolio, PBP1710 represents an important step in expanding Prestige Biopharma's innovative pipeline across oncology and fibrosis.
We are advancing the program toward IND submission in early 2027, bringing us one step closer to translating this science into meaningful treatment options for patients.
#PBP1710 #CTHRC1 #Fibrosis #PrestigeBiopharma #FirstInClass #MonoclonalAntibody #Antifibrotic #Oncology #SolidTumors #DrugDevelopment #PreclinicalResearch #Biopharma #InnovationForLife
What if pancreatic cancer could be detected earlier through a simple blood test? At Prestige Biopharma IDC, we are working toward that goal with TASA™, our proprietary blood-based diagnostic platform designed to detect PAUF, a biomarker closely associated with pancreatic cancer.
TASA™ combines selective PAUF capture with antibody-conjugated magnetic nanoparticles to isolate even trace amounts of PAUF from blood with high precision. A secondary TAG antibody then specifically recognizes the captured PAUF complex, triggering a colorimetric signal that is quantified to determine PAUF concentration. This dual-recognition approach — where separate antibodies handle capture and detection independently — minimizes non-specific signals and enables highly sensitive, selective detection even at very low concentrations.
Looking ahead, the core technology behind TASA™ is not limited to pancreatic cancer. With the right antibodies, the platform has the potential to be adapted for other biomarkers — opening the door to a broader blood-based diagnostic platform across multiple cancer types and diseases.
Watch our full latest video to learn more about TASA™'s mechanism of action and its potential to redefine how we approach cancer diagnostics.
📽️YouTube (Full Video)
▶ https://t.co/Awfm8Wmfui (EN)
▶ https://t.co/vqyszqOoFP (KR w. EN subtitles)
#Prestige #Prestigebiopharma #IDC #Pancreaticcancer #Diagnosis #PAUF #Diagnosticplatform #TASA #BloodbasedDiagnosis #Biomarker
At Prestige Biopharma, we believe changing the outlook for pancreatic cancer starts with detecting it earlier. That belief is driving the development of TASA™, our novel PAUF-based blood diagnostic.
In pancreatic cancer, timing can define what treatment is still possible.
Too many patients are diagnosed only after the opportunity for curative intervention has passed. With fewer than 20% of cases diagnosed early, the challenge is not simply detecting pancreatic cancer, it is detecting it while there is still an opportunity to intervene with curative intent. This is the ambition behind TASA™.
Developed as a blood-based diagnostic for earlier detection, TASA™ (TAG-Assisted Switch Assay) measures circulating PAUF using our proprietary signal amplification technology. Our data show markedly elevated PAUF in the blood of pancreatic cancer patients compared with healthy subjects, providing a measurable basis for blood-based detection.
For us, the significance goes beyond developing a sensitive assay. It is about shifting diagnosis toward the curative window, when earlier knowledge may create more treatment options and the greatest opportunity to improve outcomes.
We look forward to advancing TASA™ and working with partners who share our ambition to bring pancreatic cancer detection earlier, when it has the potential to matter most.
Earlier detection. Timely intervention. Greater opportunity to change outcomes.
#PrestigeBiopharma #TASA #PancreaticCancer #EarlyDetection #Diagnostics #Oncology
Prestige Biopharma Group will support #CancerMoonshot through successful clinical trials of #PBP1510 and fight against #PancreaticCancer . As a member of #CancerX, we want to contribute to the collective effort of fighting major #cancers.
https://t.co/Nsyou2EWg2